
|Videos|April 23, 2018
Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
Author(s)Elizabeth Swisher, MD
In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in breast cancer, and the importance of understanding how resistance to these agents develops.
Advertisement
In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
4
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
5



















































































